Class of Stock [Axis]
Series F Preferred Stock [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Subscription Receivable Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Option Exchange Agreement [Member]
Exchange Agreement [Member]
Pre-funded Warrant [Member]
Legal Entity [Axis]
Sanovas Ophthalmology LLC [Member]
Sale of Stock [Axis]
Private Placement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Antidilutive Securities [Axis]
Stock Options [Member]
Warrant [Member]
Related Party [Axis]
Sanovas Ophthalmology LLC [Member]
Original Employment Agreement [Member]
Mr. Gerrans [Member]
Amended and Restated Employment Agreement [Member]
Halo Management LLC [Member]
Title of Individual [Axis]
Holders [Member]
Plan Name [Axis]
2017 Equity Incentive Plan [Member]
Statistical Measurement [Axis]
Maximum [Member]
Minimum [Member]
Consulting Firm [Member]
Award Type [Axis]
Measurement Input Type [Axis]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Expected Dividend Rate [Member]
Fair Value Common Stock [Member]
Exercise Price Range [Axis]
Exercise Price 1 [Member]
Exercise Price 2 [Member]
Short-Term Debt, Type [Axis]
Notes Payable, Other Payables [Member]
Tax Period [Axis]
No Expiration Date [Member]
Expire in 2034 [Member]
Sanovas Opthalmology [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Current Assets
Cash
Due from Sanovas
Deferred offering costs
Total Current Assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Liabilities
Current Liabilities
Accounts Payable and accrued liabilities
Due to Sanovas
Due to officer
Stockholders’ loans payable
Accrued Interest Payable
Total Liabilities
Stockholders’ Deficit:
Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.0001 par value; 80,000,000 shares authorized; 14,282,314 shares issued and outstanding at March 31, 2022 and 14,221,814 shares issued and outstanding at December 31, 2021
Additional paid in capital
Preferred stock subscription receivable
Accumulated deficit
Total Stockholders’ deficit
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
Statement [Table]
Statement [Line Items]
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares designated
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Expenses
General and Administrative Expenses
Research and Development
Stock-based compensation
Total Expenses
Interest expense
Net Loss
Net Loss per share - basic and diluted
Weighted average number of common shares outstanding during the period- basic and diluted
Balance
Balance, shares
Stock purchased by investors
Stock purchased by investors, shares
Stock based compensation
Exercise of warrants
Exercise of warrants, shares
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares
Exchange of shares owned by Sanovas Ophthalmology LLC for pre-funded warrants
Exchange of shares owned by Sanovas Ophthalmology LLC for pre-funded warrants, shares
Recission of preferred stock
Recission of preferred stock, shares
Deferred costs
Net loss
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Net of Deferred costs
Statement of Cash Flows [Abstract]
Cash Flows From Operating Activities
Net Loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation expense
Increase in current assets
Expenses paid by Sanovas on behalf of Company, net
Increase in accounts payable and accrued liabilities
(Increase) decrease in deferred offering costs
Increase in accrued interest
Total adjustments
Net cash used in operating activities
Cash Flows From Financing Activities
Proceeds from common stock sold, net of costs
Proceeds from exercise of warrants
Advances from officer
Decrease in stockholders’ refund payable
Net cash provided by financing activities
Net increase (decrease) in cash
Cash at beginning of period
Cash at end of period
Supplemental information:
Retirement of due to Sanovas through the issuance of common stock to Sanovas Ophthalmology LLC (Note C)
Exchange of common stock by Sanovas Ophthalomology LLC for pre-funded warrants
Accounting Policies [Abstract]
HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN
SIGNIFICANT ACCOUNTING POLICIES
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Equity [Abstract]
COMMON AND PREFERRED STOCK
Stock Plan
STOCK PLAN
Warrants
WARRANTS
Debt Disclosure [Abstract]
NOTES PAYABLE
Income Tax Disclosure [Abstract]
INCOME TAXES
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Presentation
Cash Equivalents
Deferred Offering Costs
Use of Estimates
Income Taxes
Income (Loss) Per Common Share
Stock-based compensation
Research and Development costs
Recent Accounting Pronouncements
Offering Costs
SCHEDULE OF RELATED PARTY TRANSACTIONS
SCHEDULE OF STOCK OPTION ACTIVITY
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE
SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS
SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS
SCHEDULE OF WARRANTS ACTIVITY
SCHEDULE OF WARRANTS OUTSTANDING
Percentage of option to purchase of common stock
Common stock, shares exchange
Warrant, shares exchanged
Warrant exercise price
Retained Earnings (Accumulated Deficit)
Proceeds from Issuance of Private Placement
Repayments of Related Party Debt
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Unrecognized tax benefits
Accrued penalties and interest
Antidilutive securities excluded from computation of earnings per share
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Line Items]
Balance due from Sanovas – beginning of year
Costs paid by Sanovas on the Company’s behalf
Costs of Sanovas allocated to the Company
Repayment of amounts charged by Sanovas, net
Subtotal
Retirement of due to Sanovas through the issuance of 390,358 and 358,126 shares of common stock in 2021 and 2020, respectively, to Sanovas Ophthalmology
Balance due to (from) Sanovas - end of year
Balance due from Sanovas – beginning of period
Proceeds from (repayment of) costs charged by Sanovas to the Company, net
Balance due to Sanovas - end of period
Number of issuance of shares due to retirement
Related party cost
Value of shares issuance to offset due amounts
Due to officer
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Number of restricted shares issued
Percentage of shares issued
Number of shares issued during period
Rescind, shares
Shares issued price per share
Sale of stock, shares issued
Preferred stock, voting right
Preferred stock, dividend
Preferred stock, conversion price
Proceeds from issuance of preferred stock
Schedule Of Stock Option Activity
Stock Options, Outstanding, Beginning Balance
Weighted average exercise price, beginning balance
Stock Options, Granted
Weighted average exercise price, granted
Stock Options, Canceled
Weighted average exercise price, canceled
Stock Options, Exercised
Weighted average exercise price, exercised
Stock Options, Outstanding, Ending Balance
Weighted average exercise price, ending balance
Stock Options, Outstanding, Ending Balance
Weighted average exercise price, ending balance
Schedule Of Stock Options Outstanding And Exercisable
Exercise price
Number of options, outstanding
Weighted average remaining contractual life
Number of options, exercisable
Risk-free interest rates
Expected life in years
Expected volatility
Expected dividend yield
Fair value common stock
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock shares reserved for future issuance
Number of stock options to purchase common stock
Exercise price
Options, vesting period
Aggregate fair value of stock options
Stock-based compensation expense
Unrecognized compensation expense
Weighted-average period for recognition
Fair value of share price
Fair value of option grant price per share
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value common stock
Expected life in years
Schedule Of Warrants Activity
Stock warrants issued, beginning balance
Weighted average exercise price, beginning balance
Warrants issued, granted
Weighted average exercise price, granted
Warrants issued, canceled
Weighted average exercise price, canceled
Warrants issued, exercised
Weighted average exercise price, exercised
Stock warrants issued, ending balance
Weighted average exercise price, ending balance
Stock warrants issued, ending balance
Weighted average exercise price, ending balance
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price
Number outstanding
Weighted average remaining contractual life
Number exercisable
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plan Disclosure [Line Items]
Warrants, term
Warrants estimated fair value
Exercisable, exercise price per shares
Schedule of Short-Term Debt [Table]
Short-Term Debt [Line Items]
Debt instrument, face amount
Interest Rate
Maturity Date
Accrued interest
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards, Limitations on Use
Operating loss carryforwards
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Assets, Operating Loss Carryforwards
Deferred tax assets applicable to accruals
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Subsequent Event [Table]
Subsequent Event [Line Items]
Proceeds from sale of stock
Number of shares sold during the period
Discharge amount
Option Exchange Agreement [Member].
Sanovas Ophthalmology LLC [Member].
Stock Options [Member].
Subscription Receivable Preferred Stock [Member]
Deferred Offering Costs [PolicyText Block]
Shares issued for repayment of debt value.
Stock issued during period value retirement.
Stock issued during period shares retirement.
Sanovas Ophthalmology LLC [Member]
Stock issued during period value for exchange of shares.
Stock issued during period value for recission of preferred stock.
Original Employment Agreement [Member].
Mr. Gerrans [Member]
Amended and Restated Employment Agreement [Member].
Halo Management LLC [Member]
Shares issued for repayment of debt shares.
2017 Equity Incentive Plan [Member].
Stock issued during period shares for exchange of shares.
Stock issued during period shares for recission of preferred stock.
Change in stockholders refund payable.
LLC for prefunded warrants.
Preferred stock shares designated.
Consulting Firm [Member]
Number of common stock shares exchanged.
Due to related parties.
Due to related parties gross.
Stock Plan Disclosure [Text Block].
Fair value of share price.
Warrants Disclosure [Text Block].
No Expiration Date [Member]
Expire in 2034 [Member]
Exercisable exercise price per share.
Deferred tax assets applicable to accruals.
Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price granted.
Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price cancelled.
Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price exercised.
Schedule Of Warrant Outstanding [Table Text Block]
Exercise Price 1 [Member]
Exercise Price 2 [Member]
Share based compensation arrangement by share based payment award other than options exercisable number.
Exchange Agreement [Member]
Holders [Member]
Pre-funded Warrant [Member]
Fair Value Common Stock [Member]
Increase in accrued interest payable.
Adjustment deferred costs.
Offering Cost [Policy Text Block]
Increase decrease in deferred assets
Sanovas Ophthalmology LLC [Member] [Default Label]
Assets, Current
Assets
Liabilities [Default Label]
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Shares, Outstanding
Increase (Decrease) in Operating Assets
IncreaseDecreaseInDeferredAssets
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities
Net Cash Provided by (Used in) Operating Activities
ChangeInStockholdersRefundPayable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
LLCForPrefundedWarrants
Compensation Related Costs, Policy [Policy Text Block]
DueToRelatedParties
Proceeds from (Repayments of) Related Party Debt
Due to Officers or Stockholders
Warrants and Rights Outstanding, Measurement Input
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms